
Carbon Black (N110) - India CAS: 1333-86-4

The July 1, 2026 pharmaceutical supply chain review highlights the latest drug shortage risks. While logistics for Indian and Chinese APIs continue improving, critical antibiotics, sterile injectables, and GLP-1 manufacturing inputs remain key procurement priorities.

India’s latest DAP tender attracted record oversubscription, underscoring the country’s defensive buying stance. The move signals that global phosphate prices may stay high as demand in India remains robust. Analysts project a continued upward trend for DAP prices amid supply constraints.

The first half of 2026 exposed major vulnerabilities in pharmaceutical supply chains. API concentration, shipping disruptions, and logistics risks are reshaping procurement strategies for H2 2026 and beyond.

India's temporary customs duty exemption on Monoethylene Glycol expires at midnight, creating a major turning point for polyester manufacturers and chemical buyers. As Gulf supply improves and production costs ease, procurement teams must balance lower international prices against higher landed costs before finalizing Q3 purchasing strategies.

China's soda ash market continues to face domestic oversupply despite months of global trade disruptions. As freight costs begin to soften following lower energy prices, buyers across Europe and Asia are reassessing the competitiveness of Chinese soda ash against higher-cost regional production heading into Q3 2026.

As H2 2026 approaches, vanillin buyers must navigate a complex landscape of natural, bio‑based, and synthetic sourcing options. This article compares cost, regulatory compliance, and clean‑label appeal to help manufacturers make informed contract decisions.
We're committed to your privacy. Tradeasia uses the information you provide to us to contact you about our relevant content, products, and services. For more information, check out our privacy policy.